Enlivex Therapeutics Ltd.
ENLV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $545 | $835 | $777 | $546 |
| Gross Profit | -$545 | -$835 | -$777 | -$546 |
| % Margin | – | – | – | – |
| R&D Expenses | $10,126 | $19,235 | $18,693 | $12,881 |
| G&A Expenses | $4,913 | $6,139 | $6,702 | $6,240 |
| SG&A Expenses | $4,913 | $6,139 | $6,702 | $6,240 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$48 | $4,021 | $402 | $167 |
| Operating Expenses | $14,991 | $29,395 | $25,797 | $19,288 |
| Operating Income | -$15,536 | -$29,395 | -$25,797 | -$19,288 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $522 | $327 | -$5,263 | $4,820 |
| Pre-Tax Income | -$15,014 | -$29,068 | -$31,060 | -$14,468 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15,014 | -$29,068 | -$31,060 | -$14,468 |
| % Margin | – | – | – | – |
| EPS | -0.73 | -1.56 | -2.31 | -0.54 |
| % Growth | 53.2% | 32.5% | -327.8% | – |
| EPS Diluted | -0.73 | -1.56 | -2.31 | -0.54 |
| Weighted Avg Shares Out | 20,514 | 18,574 | 18,395 | 17,860 |
| Weighted Avg Shares Out Dil | 20,514 | 18,574 | 18,395 | 17,860 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,069 | $1,565 | $835 | $120 |
| Interest Expense | $13 | $14 | $5,263 | $328 |
| Depreciation & Amortization | $545 | $835 | $777 | $546 |
| EBITDA | -$14,469 | -$28,219 | -$25,020 | -$18,742 |
| % Margin | – | – | – | – |